Table 3.
Summary of patient data in the reference group.
| Lab no. | Sex | Age | WBC counts (×103/µl) [3.99–10.39] | Lym counts (×103/µl) [0.79–4.99] | PD-1+ [25 high-power field] lym counts | PD-1+/CD8+ ratio value | Tumor PD-L1 expression | Extent of tumor resection | Tumor location | R/T | C/T (TMZ) | GKS | CCRT | ADCTA | KPS [before] | KPS [after] | Status | OS (month) [2014/12/31] | PFS (month) | Isocitrate dehydrogenase 1 (IDH1) mutation by DNA sequencing | IDH1 IHC expression (expression%, staining intensity; DP, FP or N) | Methylguanine-DNA methyltransferase methylation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ref-01 | M | 45 | 12.4 | 1.79 | 7 | 0.09 | No | Total excision | Left frontal | − | − | − | − | − | ≥70 | − | EX | 8.53 | 1.63 | Absent | 0%, N | M |
| Ref-03 | F | 52 | 8.3 | 5.32 | 6 | 0.09 | No | Stereotatic biopsy | Left basal ganglion | + | + | + | + | − | ≥70 | − | EX | 1.6 | 1.6 | Absent | 0%, N | M |
| Ref-04 | F | 76 | 7.81 | 2.4 | 122 | 0.43 | No | Total excision | Left T-P | − | − | − | − | − | ≥70 | − | EX | 3.27 | 1.63 | Absent | 0%, N | M |
| Ref-05 | M | 54 | 7.37 | 0.81 | 904 | 0.90 | No | Total excision | Left temporal | + | + | + | + | − | <70 | − | EX | 25.07 | 13.2 | Absent | 0%, N | M |
| Ref-07 | F | 45 | 10.39 | 1.39 | 40 | 0.39 | No | Stereotatic biopsy | Left T-O | − | − | − | − | − | <70 | − | EX | 5.87 | 1.23 | Absent | 0%, N | M |
| Ref-08 | M | 46 | 9.96 | 1.7 | 41 | 0.08 | Yes | Partial excision | Right F-P-T | + | + | + | + | − | ≥70 | − | EX | 4.43 | 4.37 | Absent | 0%, N | M |
| Ref-11 | M | 56 | 8.11 | 1.76 | 48 | 0.62 | Yes | Total excision | Gyrus | + | − | − | − | − | <70 | − | EX | 22.87 | 12.43 | Absent | 0%, N | M |
| Ref-12 | M | 73 | 10.36 | 1.14 | 34 | 0.16 | Yes | Total excision | Right T-O | + | − | − | − | − | <70 | − | EX | 5.27 | 2.9 | Absent | 0%, N | M |
| Ref-13 | M | 78 | 9.03 | 1.66 | 170 | 0.56 | Yes | Total excision | Left temporal | + | + | − | + | − | ≥70 | − | EX | 9.33 | 2.5 | Absent | 0%, N | M |
| Ref-14 | F | 57 | 4.36 | N/A | 41 | 0.15 | No | Total excision | Left frontal | + | + | − | + | − | ≥70 | − | EX | 30.9 | 9.57 | Absent | 0%, N | UM |
| Ref-15 | F | 50 | 5.46 | 1.99 | 0 | 0.00 | No | Total excision | Right frontal | − | − | − | − | − | <70 | − | EX | 0.2 | 0.2 | Absent | 15%, weak, N | M |
| Ref-17 | M | 25 | 16.46 | 0.92 | 44 | 0.33 | Yes | Total excision | Left frontal and basal ganglion | − | − | − | − | − | ≥70 | − | EX | 3.37 | 3.37 | Absent | 0%, N | M |
| Ref-20 | M | 49 | 8.79 | 1.16 | 0 | 0.00 | Yes | Total excision | Right P-O | + | + | + | + | − | ≥70 | − | EX | 4.63 | 1.7 | Absent | 0%, N | M |
| Ref-26 | F | 40 | 8.97 | 2.07 | 36 | 0.44 | No | Total excision | Left frontal | − | − | + | − | − | ≥70 | − | EX | 11.23 | 3.27 | Absent | 0%, N | UM |
| Ref-27 | F | 69 | 11.97 | 2.38 | 93 | 0.62 | No | Excision | Right frontal | − | − | − | − | − | ≥70 | N/A | EX | 6.4 | 2.9 | Absent | 0%, N | UM |
| Ref-28 | F | 31 | 16.75 | 1.19 | 27 | 2.45 | Yes | Stereotactic biopsy | Right parietal | + | − | − | − | − | ≥70 | N/A | EX | 8.23 | 8 | Present R132H | 100%, strong, DP | M |
| Ref-29 | F | 68 | 11.06 | 1.36 | 0 | 0.00 | Yes | Stereotactic biopsy | Left parietal | − | − | + | − | − | ≥70 | N/A | EX | 4.73 | 4.33 | Absent | 0%, N | M |
| Ref-30 | M | 78 | 9.58 | 1.69 | 78 | 0.43 | No | Excision | Left frontal | − | + | + | − | − | ≥70 | N/A | EX | 9.7 | 1.33 | Absent | 0%, N | M |
| Ref-31 | M | 52 | 8.14 | 0.83 | 59 | 0.17 | No | Excision | Left parieto-temporal | − | − | − | − | − | ≥70 | − | EX | 2.97 | 2.2 | Absent | 0%, N | M |
| Ref-32 | F | 72 | 8.6 | 2.28 | 16 | 0.16 | Yes | Stereotatic biopsy | Left frontal | − | − | − | − | − | ≥70 | − | EX | 3.47 | 3.47 | Absent | 0%, N | M |
Symbols: +, received therapy; −, did not receive therapy; Lym, lymphocyte; R/T, radiotherapy; GKS, gamma knife; CCRT, concomitant chemoradiotherapy; ADCTA, autologous dendritic cell/tumor antigen immunotherapy; KPS, Karnofsky Performance Score (KPS before, before ADCTA; KPS after, after ADCTA); OS, overall survival; PFS, progression-free survival; tumor location: T, temporal; F, frontal; O, occipital; P, parietal; SU, patient still alive on 2014/12/31; EX, patient expired; DP, diffuse positive; FP, focal positive; N, negative; M, methylation present; UM, methylation absent.